DCTH vs. CLPT, OBIO, QIPT, STIM, DRTS, TELA, KRMD, PROF, BLUA, and ALUR
Should you be buying Delcath Systems stock or one of its competitors? The main competitors of Delcath Systems include ClearPoint Neuro (CLPT), Orchestra BioMed (OBIO), Quipt Home Medical (QIPT), Neuronetics (STIM), Alpha Tau Medical (DRTS), TELA Bio (TELA), KORU Medical Systems (KRMD), Profound Medical (PROF), BlueRiver Acquisition (BLUA), and Allurion Technologies (ALUR). These companies are all part of the "surgical & medical instruments" industry.
Delcath Systems (NASDAQ:DCTH) and ClearPoint Neuro (NASDAQ:CLPT) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, profitability, earnings, analyst recommendations, valuation, community ranking, institutional ownership, media sentiment and risk.
In the previous week, ClearPoint Neuro had 1 more articles in the media than Delcath Systems. MarketBeat recorded 3 mentions for ClearPoint Neuro and 2 mentions for Delcath Systems. Delcath Systems' average media sentiment score of 1.10 beat ClearPoint Neuro's score of 0.06 indicating that Delcath Systems is being referred to more favorably in the media.
Delcath Systems and ClearPoint Neuro both received 20 outperform votes by MarketBeat users. However, 86.96% of users gave ClearPoint Neuro an outperform vote while only 20.00% of users gave Delcath Systems an outperform vote.
Delcath Systems has a beta of 0.53, indicating that its share price is 47% less volatile than the S&P 500. Comparatively, ClearPoint Neuro has a beta of 0.97, indicating that its share price is 3% less volatile than the S&P 500.
ClearPoint Neuro has a net margin of -92.21% compared to Delcath Systems' net margin of -2,308.86%. ClearPoint Neuro's return on equity of -83.94% beat Delcath Systems' return on equity.
Delcath Systems presently has a consensus target price of $18.50, suggesting a potential upside of 242.59%. ClearPoint Neuro has a consensus target price of $12.00, suggesting a potential upside of 121.40%. Given Delcath Systems' higher possible upside, equities analysts plainly believe Delcath Systems is more favorable than ClearPoint Neuro.
ClearPoint Neuro has higher revenue and earnings than Delcath Systems. ClearPoint Neuro is trading at a lower price-to-earnings ratio than Delcath Systems, indicating that it is currently the more affordable of the two stocks.
61.1% of Delcath Systems shares are owned by institutional investors. Comparatively, 30.1% of ClearPoint Neuro shares are owned by institutional investors. 17.9% of Delcath Systems shares are owned by company insiders. Comparatively, 6.1% of ClearPoint Neuro shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
ClearPoint Neuro beats Delcath Systems on 9 of the 16 factors compared between the two stocks.
Get Delcath Systems News Delivered to You Automatically
Sign up to receive the latest news and ratings for DCTH and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding DCTH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Delcath Systems Competitors List
Related Companies and Tools
